Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

被引：8
|
作者：
Stein, Alexander
Binder, Mascha
Al-Batran, Salah-Eddin
Hinke, Axel
Waberer, Lisa
Goekkurt, Eray
Meyer, Tobias
Statovci, Donjete
Depenbusch, Reinhard
Riera-Knorrenschild, Jorge
Lorenzen, Sylvie
Ettrich, Thomas Jens
Doerfel, Steffen
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
机构：
[1] Univ Hamburg Eppendorf, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] UCT Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[4] CCRC, Dusseldorf, Germany
[5] Krankenhaus Nordwest IKF, Frankfurt, Germany
[6] Univ Canc Ctr Hamburg, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[7] AIO Studien GmbH, Berlin, Germany
[8] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany
[9] Universitatsklinikum, Giessen, Germany
[10] Tech Univ Munich, Dept Internal Med Hematol Med Oncol 3, Klin Rechts Isar, Munich, Germany
[11] Ulm Univ Hosp, Ulm, Germany
[12] Onkozentrum Dresden, Dresden, Germany
[13] Hamatologisch Onkolog Praxis Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3561
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3561
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) - Final Results of the phase II AVETUX trial (AIO-KRK-0216)
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas
    Doerfel, Steffen
    Al-Batran, Salah
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Tintelnot, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)
    Stein, Alexander
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas Jens
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): The phase II AVETUX-CRC trial (AIO KRK 0216).
    Stein, Alexander
    Binder, Mascha
    Bokemeyer, Carsten
    Al Batran, Salah Eddin
    Hinke, Axel
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)
    Stintzing, S.
    Dechow, T. N.
    Vehling-Kaiser, U.
    Lorenzen, S.
    Hannig, C-V.
    Schwaner, I.
    Von Weikersthal, L. Fischer
    Puchtler, G.
    Binder, M.
    Held, S.
    Heinrich, K.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S729 - S729
  • [5] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    Hoehler, T.
    von Wichert, G.
    Schimanski, C.
    Kanzler, S.
    Moehler, M. H.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hofheinz, R.
    Hacker, U. T.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1408 - 1413
  • [6] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    T Hoehler
    G von Wichert
    C Schimanski
    S Kanzler
    M H Moehler
    A Hinke
    T Seufferlein
    J Siebler
    A Hochhaus
    D Arnold
    M Hallek
    R Hofheinz
    U T Hacker
    British Journal of Cancer, 2013, 109 : 1408 - 1413
  • [7] Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal Cancer
    Kozuch, Peter
    Malamud, Steve
    Wasserman, Carrie
    Homel, Peter
    Mirzoyev, Takhir
    Grossbard, Michael
    CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 38 - 42
  • [8] A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
    Berlin, Jordan
    Bendell, Johanna C.
    Hart, Lowell L.
    Firdaus, Irfan
    Gore, Ira
    Hermann, Robert C.
    Mulcahy, Mary F.
    Zalupski, Mark M.
    Mackey, Howard M.
    Yauch, Robert L.
    Graham, Richard A.
    Bray, Gordon L.
    Low, Jennifer A.
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 258 - 267
  • [9] Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
    Oh, D-Y.
    Arkenau, T.
    Lee, K-W.
    Alsina, M.
    Marti, F. M.
    Chung, I. J.
    Saif, W.
    Wang, D.
    O'Dwyer, P.
    Chau, I.
    Lee, M-A.
    Chong, E.
    Hilger-Rolfe, J.
    Cole, G., Jr.
    Kim, S. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S428 - S428
  • [10] Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial
    Fumet, J-D.
    Chibaudel, B.
    Bennouna, J.
    Borg, C.
    Martin-Babau, J.
    Cohen, R.
    Fonck, M.
    Taieb, J.
    Thibaudin, M.
    Limagne, E.
    Blanc, J.
    Bertaut, A.
    Ghiringhelli, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S551 - S551
12345